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In serum, mouse embryonic stem cells (mESCs)
fluctuate between a naive inner cell mass (ICM)-like
state and a primed epiblast-like state, but when
cultured with inhibitors of the mitogen-activated
protein kinase (MAPK) and glycogen synthase kinase
3 pathways (2i), they are harnessed exclusively in
a distinct naive pluropotent state, the ground state,
that more faithfully recapitulates the ICM. Under-
standing the mechanism underlying this naive
pluripotent state will be critical for realizing the full
potential of ESCs. We show here that PRDM14,
a PR-domain-containing transcriptional regulator,
ensures naive pluripotency through a dual mecha-
nism: antagonizing activation of the fibroblast growth
factor receptor (FGFR) signaling by the core pluripo-
tency transcriptional circuitry, and repressing ex-
pression of de novo DNA methyltransferases that
modify the epigenome to a primed epiblast-like state.
PRDM14 exerts these effects by recruiting polycomb
repressive complex 2 (PRC2) specifically to key tar-
gets and repressing their expression.
INTRODUCTION
Mouse embryonic stem cells (mESCs) are pluripotent and self-
renewing cells derived from the inner cell mass (ICM) of blasto-
cysts (Evans and Kaufman, 1981). The mESCs have the capacity368 Cell Stem Cell 12, 368–382, March 7, 2013 ª2013 Elsevier Inc.to contribute to chimeric animals by differentiating into all the
somatic lineages as well as the germline when introduced back
into the blastocysts (Bradley et al., 1984). The mESCs have
been used not only as a vehicle to generate gene-knockout
mice by homologous recombination (Smithies, 2005), but also
as a starting material for recapitulation and investigation of
the developmental processes in vitro (Murry and Keller, 2008).
The establishment of human (h) ESCs and induced pluripotent
stem cells (iPSCs) has heightened the prospects of investigating
human development in vitro and of generating cells of medical
relevance for regenerative medicine (Takahashi et al., 2007;
Thomson et al., 1998), although hESCs/hiPSCs exhibit key
differences in their pluripotent properties from mESCs and the
underlyingmechanism for these differences requires clarification
(Rossant, 2011).
The mechanism underlying the pluripotency and self-renewal
has been studied most extensively in mESCs cultured in serum,
and the results have shown that the ESC state is founded on the
core regulatory circuitry of transcription factors for pluripotency,
consisting of OCT4, SOX2, and NANOG, which is stabilized
by leukemia inhibitory factor (LIF) and WNT signaling and is de-
stabilized for differentiation by fibroblast growth factor (FGF)
signaling (Silva and Smith, 2008; Young, 2011). Notably, OCT4,
SOX2, and NANOG, while maintaining the pluripotent state
of ESCs, activate FGF4, which is a key trigger for differenti-
ation (Kunath et al., 2007), and therefore, ESCs must have
a critical mechanism to antagonize the self-activating differenti-
ation signal. Reflecting this ‘‘ambivalence’’ of the core regulatory
circuitry, mESCs in serum show heterogeneity and consist of
at least two populations, one with gene expression similar to
the naive ICM state and the other with gene expression simi-
lar to the primed epiblast state, and these two populations
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state exhibits metastability and dynamic equilibrium, and that
these characteristics are regulated by transcriptional circuitry
and signaling inputs (Chambers et al., 2007; Hayashi et al.,
2008; Toyooka et al., 2008).
A recent study has shown that inhibition of the mitogen-
activated protein kinase/extracellular regulated kinase (MAPK/
ERK) pathway, which, in response to autocrine FGF4, primes
the differentiation of mESCs (Kunath et al., 2007), and inhibition
of the glycogen synthase kinase 3 (GSK3) pathway, which desta-
bilizes the core regulatory circuitry through transcription factor 3
(TCF3) (Wray et al., 2011), by their specific inhibitors [MAPK/ERK
kinase inhibitor (MEKi, PD0325901) and GSK3 inhibitor (GSK3i,
CHIR99021), known as 2i] is sufficient to maintain the pluripo-
tency and self-renewal of mESCs (Ying et al., 2008). mESCs in
2i appear to be homogeneous, and have a gene expression
profile and an epigenome that are different from those of a naive
ESC population in serum, and more similar to those of ICM cells
(Marks et al., 2012; Ying et al., 2008). These findings not only
demonstrate that key differentiation-inducing signals play a
dominant role in destabilizing the pluripotent state, but also
necessitate the (re-)evaluation of the function of transcriptional
regulators for pluripotency under the 2i condition, free from
differentiation-inducing signals.
PR-domain-containing 14 (Prdm14) has been identified as
a critical regulator for the specification of primordial germ cells
(PGCs) from the epiblast (Yamaji et al., 2008). Subsequently,
PRDM14 was shown to be a component of the core transcrip-
tional regulatory circuitry and to function as a regulator for
hESC identity with its ability to directly regulate POU5F1 (Chia
et al., 2010). In mESCs, Prdm14 was shown to repress extraem-
bryonic endoderm (ExEn) differentiation (Ma et al., 2011). How-
ever, both studies involved RNAi-mediated partial knockdown
(KD) of PRDM14/Prdm14 in serum, and the precise function
and the mechanism of the action of PRDM14 in ESCs remain
elusive. Here, using the Prdm14-knockout model in serum and
in 2i, we show that PRDM14 safeguards naive pluripotency by
a dual mechanism.
RESULTS
Prdm14 Is Critical for ESC Derivation in Serum
To explore the function of Prdm14 in mESCs, we examined
the expression of Prdm14 in ESCs cultured in serum and
LIF on mouse embryonic feeders (MEFs) (with serum+LIF on
MEFs hereafter referred to as serum, unless otherwise specified)
using ESCs bearing Prdm14 DEx2-5-mVenus (P14DExV) trans-
genes, which precisely recapitulate endogenous Prdm14 ex-
pression (Figure S1, available online) (Yamaji et al., 2008).
ESCs in serum showed heterogeneous expression of P14DExV
and those with high P14DExV showed high NANOG (Figure 1A).
ESCs with high P14DExV sorted by fluorescence activated cell
sorting (FACS) (11.8%) showed higher expression of endoge-
nous Prdm14 and genes associated with naive pluripotency
(Nanog, Zfp42/Rex1, Klf2, Klf4, Esrrb, Tbx3, and Tcl1), and
lower expression of genes associated with epiblast/ectoderm
(Dnmt3a, Dnmt3b, Nestin, Krt18, and Fgf5) and mesoderm
development (Tbx6 and T), than cells with low/no P14DExV
(39.9%) (Figures 1B and 1C). Notably, genes associated withCendoderm (Sox7,Gata6,Sox17,Gata4, andPdgfra) and trophec-
toderm (TE) (Tead4, Gata3, and Cdx2) development did not
show consistent enrichment in either population (Figure 1C).
Pou5f1 (also known as Oct4) was expressed at a similar level
in both P14DExV-high and P14DExV-low/no cells (Figure 1C).
Thus, ESCs in serum consist of a population with naive ICM-
like properties and a population with primed epiblast-like proper-
ties, and Prdm14 is associated with the population with naive
ICM-like properties.
To examine whether ESCs are derived under a Prdm14-
deficient condition, we isolated blastocysts from Prdm14
heterozygously+/ mutant crossings (Yamaji et al., 2008) and
cultured them in serum. Out of 164 blastocysts, we established
52 ESC lines, with no Prdm14 homozygously/ mutant
genotype (Figure 1D). To rule out the minor possibility that
there was no Prdm14/ blastocyst at the outset of culture,
we isolated blastocysts from Prdm14+/ crossings, geno-
typed the blastocysts using immunoisolated TE, and cultured
Prdm14+/+, +/, / ICMs for ESC derivation. As shown in Fig-
ure 1E, while we obtained 5 and 7 ESC lines out of 9
Prdm14+/+ and 22 Prdm14+/ ICMs, respectively, we obtained
no ESC line out of 8 Prdm14/ ICMs. We conclude that
Prdm14 is critical for ESC derivation in serum.
Prdm14–/– ESC-like Cells in 2i
In contrast to ESCs in serum, ESCs in 2i+LIF on MEFs (we
used MEFs for efficient adhesion of ESCs, hereafter referred
to as 2i, unless otherwise specified) showed round morphology
and uniform expression of P14DExV and NANOG (Figure 2A).
We examined whether Prdm14/ ESC-like cells are derived
in 2i. When we cultured blastocysts from Prdm14+/ crossings
in 2i, we obtained 15 and 18 ESC lines out of 19 Prdm14+/+
and 20 Prdm14+/ blastocyst outgrowths, respectively, and,
remarkably, 17 ESC-like lines out of 18 Prdm14/ blastocyst
outgrowths (Figure 2B). The Prdm14/ ESC-like cells showed
a flat morphology, but exhibited alkaline phosphatase (AP)
activity and expressed OCT4, SOX2, NANOG, and ESRRB
at levels similar to those in Prdm14+/+ ESCs (Figures 2C and
2D). These findings indicate that with elimination of differen-
tiation signals and/or enhancement of the core pluripotency
circuitry by 2i, an ESC-like state can be established without
PRDM14.
We next examined whether the established Prdm14/ ESC-
like cells can be maintained when transferred to serum. We
dissociated Prdm14+/+ and Prdm14/ cells cultured in 2i into
single cells and examined their AP-positive colony formation in
2i or in serum. In contrast to Prdm14+/+ cells, although dissoci-
ated single Prdm14/ cells formed AP-positive colonies in 2i,
they failed to do so in serum (Figure 2E). We established
Prdm14/ lines that constitutively express exogenous Avi-
(a substrate sequence for the biotin ligase; Cull and Schatz,
2000) and EGFP-tagged PRDM14 (the Prdm14/: AG-P14
cells), which, unlike negative controls expressing EGFP targeted
to the nucleus (the Prdm14/: nGFP cells), showed a level of
AP-positive colony formation ability comparable to those of
Prdm14+/+ cells in serum (Figures 2F and 2G). These findings
indicate that the Prdm14/ ESC-like state is highly vulnerable
to differentiation in serum and that AG-P14 rescues PRDM14




Figure 1. Prdm14 Is Critical in ESC Derivation in Serum
(A) Expression of P14DExV (green), NANOG (red), and OCT4 (blue), and their merge with Hoechst (white) in ESCs in serum. Bar, 20 mm.
(B) FACS of P14DExV ESCs cultured in serum.
(C) Expression levels of the indicated genes in P14DExV-high cells. For each gene, the average Ct value in P14DExV-high cells was subtracted from that in
P14DExV-low/no cells and is shown (log2) with SEMs (two technical replicates).
(D and E) ESC derivation in serum from blastocysts (genotype predetermined in E) from Prdm14+/ crossings.
See also Figure S1 and Table S6.
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We next explored the properties of Prdm14/ ESC-like cells in
2i. We noted that the rate of increase in the number ofPrdm14/
cells was reduced compared to that of Prdm14+/+ cells (Fig-
ure 2H). We compared the proliferation of single Prdm14+/+
and Prdm14/ cells adhered on MEFs by counting the number
of cells in colonies after 4 days without passage; the colonies
from single Prdm14/ cells bore a significantly reduced number
of cells compared to those from Prdm14+/+ cells (Figures S2A
and S2B). The cell cycle analysis by FACS showed that
Prdm14/ cells were distributed more frequently in G1 phase
and less frequently in S phase than Prdm14+/+ cells (G1 phase:
26.4% in Prdm14/ versus 23.8% in Prdm14+/+, p < 0.005; S
phase: 37.2% (/) versus 40.5% (+/+), p < 0.02) (Figures S2C
and S2D). We also found a slight but significant elevation in the
rate of apoptosis inPrdm14/ cells (0.79% inPrdm14/ versus
0.30% in Prdm14+/+, p < 0.04) (Figures S2E and S2F).370 Cell Stem Cell 12, 368–382, March 7, 2013 ª2013 Elsevier Inc.We examined whether the Prdm14/ cells form teratomas.
The Prdm14/ cells formed teratomas, but they were smaller
than those formed from the Prdm14+/+ cells (Figures 2I–2K).
Moreover, unlike the teratomas of Prdm14+/+ cells, those of
Prdm14/ cells rarely exhibited foci of immature cells and
consisted mainly of differentiated neurons, although they con-
tained differentiated cells of three germ layers (Figure 2L, Fig-
ure S2G). We evaluated whether the Prdm14/ cells contribute
to chimeras. Interestingly, Prdm14/ cells contributed to chi-
meras efficiently, but did so to a lesser degree compared to
Prdm14+/+ cells (Figures 2Mand 2N). The tetraploid complemen-
tation assay demonstrated that, as predicted from the pheno-
type of the Prdm14/ mice (Yamaji et al., 2008), the tetraploid
embryos rescued by a high contribution of the Prdm14/
cells, but not the Prdm14+/+ cells, lacked PGCs completely
(Figures S2H–S2J). Collectively, these findings demonstrate
that Prdm14/ ESC-like cells in 2i show retarded proliferation,
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and lack the ability to differentiate into PGCs.
Genome-Wide Analysis of Genes Regulated by
PRDM14 in 2i
To determine the mechanism underlying the key phenotypes of
Prdm14/ ESC-like cells, we compared the global transcription
profiles of Prdm14/ cells to those of Prdm14+/+ cells in 2i by
microarray analysis. We identified 280 and 465 genes upregu-
lated and downregulated, respectively, more than 2-fold in
Prdm14/ cells as compared to Prdm14+/+ cells (Figure 3A,
Table S1). Consistent with the propensity of Prdm14/ cells to
differentiate into neurons in teratomas, the population of upregu-
lated genes was enriched with genes associated with neuron
development and also with those for other developmental
processes, such as ‘‘Cell development,’’ ‘‘Embryonic develop-
ment,’’ and ‘‘Anatomical structure development’’ in gene
ontology (GO) terms (Figure 3B, Table S1). On the other hand,
the total population of downregulated genes showed relatively
poor enrichment of genes associated with GO categories (less
significant p values), but, nonetheless, were enriched with genes
for ‘‘Female meiosis sister chromatid cohesion,’’ cell death, and
phosphorylation (Figure 3C, Table S1). In agreement with the
retarded proliferation of Prdm14/ cells, they showed reduced
expression of Ccnd3 and Ccne1, key cyclins for G1-S transition
(Figure S2K). These findings indicate that the genes repressed by
PRDM14 are most typically associated with epiblast/ectoderm/
neuron development, whereas those activated by PRDM14 are
involved in more general biochemical processes.
We validated the expression of key genes by quantitative
(Q)-PCR, which confirmed that, consistent with the microarray
analysis, genes such as Tcl1 and Klf5 were downregulated,
whereas those encoding de novo DNA methyltransferases
(DNMTs), i.e., Dnmt3a, Dnmt3b, and Dnmt3l, and those involved
in enhancing the fibroblast growth factor receptor (FGFR)
signaling, such as Fgfr1, Fgfr2, Fgfbp1, Hs6st2, Epha4, and
Fgf5, were upregulated in Prdm14/ cells (Figure 3D). Consis-
tent with the findings by western blot analysis (Figure 2D),
Pou5f1, Sox2, andNanogwere not downregulated in Prdm14/
cells, indicating that PRDM14 is dispensable for the intrinsic
operation of the core circuitry.
To determine the genes directly regulated by PRDM14 in ESCs
in 2i, we performed chromatin immunoprecipitation (ChIP) of AG-
P14 using an anti-GFP antibody, followed by massively parallel
sequencing (ChIP-seq). As a negative control, we performed
ChIP-seq analysis of the Prdm14/: nGFP cells using the
same anti-EGFP antibody. The analysis of the sequence results
(Figure 3E, Figure S3A, Table S2) identified 3,608 regions with at
least one peak of 3-fold or greater enrichment (p < 104) for AG-
P14, and of these 3,608 regions, only 10 were also enriched with
nGFP (FDR < 0.003); these regions were removed from the
subsequent analyses. The 3,598 AG-P14 peaks covered
68.5% of the PRDM14-binding sites reported previously (1,622
peaks out of 2,368 peaks) (Ma et al., 2011) and identified 1,976
further PRDM14-binding sites (Figure 3E). PRDM14 binds
predominantly away from the gene promoters, with 4.1% and
23.9% of the binding sites being located within 1 kilobase (kb)
and 1–10 kb, respectively, of the nearest annotated transcription
start sites (TSSs) (Figure 3F).CThe analysis of the published database (for ESCs in serum;
Chen et al., 2008; Ma et al., 2011; Marson et al., 2008; Pasini
et al., 2010; Peng et al., 2009) revealed that the genes repressed
by PRDM14 are enriched with targets of NANOG and SUZ12,
whereas those activated by PRDM14 are enriched with targets
of STAT3 and ESRRB (Figure 3G, Table S3). In good agreement,
the regions bound by PRDM14 are, most notably, co-occupied
by ESRRB and NANOG (Figures 3H and 3I and Table S3), and
the DNA motifs overrepresented in PRDM14-bound regions
include known binding sequences for NANOG and ESRRB, as
well as for mouse and human PRDM14 (Figure 3J), suggesting
that PRDM14 represses or activates genes cooperatively with
these factors. Among the 280 and 465 genes upregulated and
downregulated, respectively, in Prdm14/ cells, 134 (47.9%)
and 101 (21.7%) genes, respectively, contain PRDM14-binding
sites within ±50 kb from their TSSs (Figure 3K and Figure S3B).
PRDM14 Activates AKT-mTORC1 Signaling
Having identified genes regulated by PRDM14, we next attemp-
ted to identify (a) gene(s) that might have an impact on the
retarded proliferation of Prdm14/ ESC-like cells. We noted
that, in addition to Ccnd3 and Ccne1, the proto-oncogene
Tcl1, which encodes a cofactor enhancing the AKT signaling
(Laine et al., 2000; Pekarsky et al., 2000) and is critical for the
proliferation of ESCs (Ivanova et al., 2006), is downregulated
(by 75%) in Prdm14/ cells (Figure 3D). We therefore exam-
ined the activity of the AKT signaling in both Prdm14+/+ and
Prdm14/ cells, and found that the level of the phosphorylation
of the Serine 240/244 of the ribosomal S6 protein (pS240/244-
S6), a key output of the mechanistic target of rapamycin com-
plex 1 (mTORC1) branch of the AKT signaling involved in cell
proliferation (Laplante and Sabatini, 2012), is reduced nearly by
half in Prdm14/ cells (p < 0.032) (Figures 4A and 4B). Consis-
tently, the level of the phosphorylation of the Threonine 389 of
p70 S6 kinase, an upstream event of pS240/244-S6, was also
reduced by 40% in Prdm14/ cells (p < 0.018) (Figures 4A
and 4B), indicating the impairment of AKT-mTORC1 signaling
in Prdm14/ cells.
We established Prdm14/ cell lines expressing exogenous
Tcl1 (the Prdm14/: TCL1 cells). These cells, in addition to the
Prdm14/: AG-P14 cells, exhibited higher levels of pS240/
244-S6 compared to the Prdm14/: nGFP cells (Figures 4C
and 4D), indicating that PRDM14 controls the level of mTORC1
signaling through Tcl1. Consistently, the Prdm14/: AG-P14
and Prdm14/: TCL1 cells showed a faster proliferation com-
pared to the Prdm14/: nGFP cells in 2i (Figure 4E). However,
when transferred to serum, the Prdm14/: AG-P14 cells con-
tinued to grow robustly in an undifferentiated state, but the
Prdm14/: TCL1 cells as well as the Prdm14/: nGFP cells
began to show differentiation, then stopped proliferating and
eventually disappeared (Figure 4F). Thus, although regulation
of Tcl1 by PRDM14 accounts for the proliferation phenotype of
the Prdm14/ cells, it does not account for the vulnerability to
differentiation in serum of the Prdm14/ cells.
PRDM14 Ensures Naive Pluripotency by Antagonizing
FGFR Signaling
We next examined the basis for the vulnerability to differentiation
















































































Genotype Blastocysts Outgrowth Passaged Established 
+/+ 29 23 19 15 
+/ 54 47 20 18 
/ 21 20 18 17 
Total 104 90 59 52 
+/+  Td = 17.2 ± 0.1 h (n=4)
Td = 19.3 ± 1.0 h (n=3)
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Figure 2. Properties of Prdm14–/– ESC-like Cells Derived in 2i
(A) Expression of P14DExV (green), NANOG (red), and OCT4 (blue), and their merge with Hoechst (white) in ESCs in 2i. Bar, 20 mm.
(B) ESC derivation in 2i from blastocysts from Prdm14+/ crossings.
(legend continued on next page)
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expression of genes for naive pluripotency and showed gene
expression changes consistent with their differentiation toward
epiblast/ectoderm (Figures 5A and 5B).
After 2-day exposure to serum, compared to Prdm14+/+ cells,
the Prdm14/ cells exhibited elevated levels of the phosphory-
lation of ERK1/2 (pERK) (Figure 5C), a key event for the priming of
ESCs to differentiation (Kunath et al., 2007). Since genes
involved in the positive regulation of the FGFR signaling are up-
regulated in the Prdm14/ cells (Figure 3D), we evaluated the
response of the Prdm14/ cells to the stimulus by FGF4,
a key FGF ligand that primes ESC differentiation (Kunath et al.,
2007). Upon FGF4 stimulus, compared to the Prdm14+/+ cells,
the Prdm14/cells (cultured in serum-free medium with
N2B27 and with GSK3i, but without MEKi and LIF) exhibited
much stronger activation of ERK, which peaked 15 min after
the stimulus, indicating that the Prdm14/ cells bear hyperreac-
tive FGFR signaling that leads to a hyperactivation of ERK
(Figure 5D).
We cultured Prdm14+/+ and Prdm14/ cells with or without
a specific inhibitor of FGFR, PD173074, as well as the MEKi.
With these inhibitors, the Prdm14/ cells continued to prolif-
erate with serum upon multiple passages (although more slowly
than the Prdm14+/+ cells), formed AP-positive colonies with
undifferentiated morphology, and retained genes for naive plu-
ripotency in serum for 1 month or longer (Figures 5E–5G).
We determined the genome-wide expression profiles of
Prdm14+/+ cells, Prdm14/ cells, and Prdm14/: AG-P14 cells
cultured in 2i, serum (2 days), serum+MEKi (2 days), and serum
without LIF (2 days) as well as those of epiblast-like cells (Ep-
iLCs) induced from ESCs (corresponding to E5.75 epiblasts;
Hayashi et al., 2011, 2012) by microarray analysis. A principal
component analysis (PCA) showed that, upon exposure to
serum, all genotypes of cells exhibited gene expression
changes toward an epiblast-like state, the extent of which ap-
peared to correlate negatively with the expression level of
Prdm14 and the presence of LIF and MEKi (Figure 5H, Table
S4). We analyzed the expression of key genes by Q-PCR and
found that, even without LIF, Prdm14/: AG-P14 cells main-
tained the expression of genes for naive pluripotency and(C) Morphology (left) and AP activity (right) of Prdm14+/+ and Prdm14/ cells in
(D) Western blot for OCT4, SOX2, NANOG, ESRRB, ERK1/2, and TUBA (a-tubulin
2i. To estimate the contribution of each protein from MEFs in each sample, the c
right (2.5 3 103 cells/lane).
(E) Colony formation from single Prdm14+/+ and Prdm14/ cells in 2i or seru
with SEMs.
(F) Representative colonies stained for AP activity of Prdm14+/+, Prdm14/, Prd
(G) AP-positive colony formation by Prdm14+/+, Prdm14/, Prdm14/: nGFP, a
each experiment are shown, with means and SEMs.
(H) Proliferation and doubling time (Td) of Prdm14
+/+ and Prdm14/ cells. The me
(log10) with SEMs.
(I) A nude mouse injected with 1 3 106 of Prdm14+/+ and Prdm14/ cells at two
(J) Teratomas from Prdm14+/+ and Prdm14/ cells generated at the contralater
(K) Weights (mg) of teratomas from Prdm14+/+ and Prdm14/ cells. Values of Prd
a line. The mean values are indicated in red.
(L) Hematoxylin-eosin (H&E) staining and immunohistochemistry (TUJ1, for neu
Arrowheads indicate foci for immature cells with dark hematoxylin staining. Bars
(M) Chimeras formed by Prdm14/ cells. An arrow indicates a BALB/c littermat
(N) Percentage of chimerism by Prdm14+/+ and Prdm14/ cells as determined b
See also Figure S2.
Cprevented the upregulation of genes associated with the
epiblast/ectoderm lineage (Figure 5I). We conclude that
PRDM14 safeguards the naive pluripotency by repressing the
FGFR signaling pathway.
To gain more insight into the relationship between the
PRDM14-dependent pathway and other known pathways for
the regulation of pluripotency, we examined the effect of
GSK3i, which stabilizes the core pluripotency network by upre-
gulating ESRRB (Martello et al., 2012), on Prdm14/ cells in
serum. Interestingly, GSK3i rescued Prdm14/ cells in serum
in terms of both their gene expression and proliferation to
a similar extent as MEKi and FGFRi (Figures S4A–S4D), indi-
cating that stabilization of the core pluripotency network over-
rides the hyperactive FGFR signaling in Prdm14/ cells.
PRDM14 Regulates Gene Expression through
Repression of De Novo DNMTs
The ChIP-seq and ChIP-Q-PCR analyses for AG-P14 revealed
that AG-P14 does not bind to Tcl1, whereas it does bind to
many of the positive regulators for FGFR signaling, including
Fgfr1, Fgfr2, Fgfbp1, Hs6st2, and Epha4 (Figures S3C and
S3D), indicating that regulation by PRDM14 of the expression
of Tcl1 is indirect, but that of the FGFR signaling regulators is
a direct effect.
Compared to Prdm14+/+ cells, the Prdm14/ cells exhibited
elevated expression of de novo DNMTs (Figures 3D and 6A).
The high expression of de novo DNMTs is a characteristic of pre-
gastrulating epiblasts (Okano et al., 1999) and EpiLCs (Hayashi
et al., 2011). Notably, AG-P14 directly bound Dnmt3a, Dnmt3b,
and Dnmt3l (Figures S3C and S3D). These findings led us to
speculate that the Prdm14/ cells, due to their high de novo
DNMT activity, may have an aberrant DNA methylation profile
similar to that of pregastrulating epiblasts, leading to DNAmeth-
ylation-based inactivation of a number of genes, including Tcl1.
We therefore examined the methylation of Tcl1. Tcl1 shows de
novo methylation around its promoter and gene body, and is
repressed in E5.75/E6.5 epiblasts and in EpiLCs (Borgel et al.,
2010; Hayashi et al., 2011). We analyzed the methylation levels
around the TSS of Tcl1 by combined bisulfite restriction analysis
(COBRA), which revealed that the regions 2 (R2) and 3 (R3) were2i. Bar, 20 mm.
) in Prdm14+/+ and Prdm14/ cells (three lines for each,53 104 cells/lane) in
ell lysate prepared without ESCs (referred to as MEFs only) was loaded on the
m. The mean AP-positive colony numbers (three lines for each) are shown,
m14/: nGFP, and Prdm14/: AG-P14 cells in 2i. Bar, 20 mm.
nd Prdm14/: AG-P14 cells in serum. Colony numbers for each genotype for
an values of Prdm14+/+ (four lines) and Prdm14/ (three lines) cells are shown
positions on the left and right sides, respectively.
al positions aligned at the same positions in each genotype. Bar, 2 cm.
m14+/+ and Prdm14/ teratomas at the contralateral sides are connected with
ronal class III b-tubulin) of teratomas from Prdm14+/+ and Prdm14/ cells.
: 1 mm (left); 500 mm (right).
e.
y inspection of the coat color.











Figure 3. Genes Regulated by PRDM14 in 2i
(A) A scatter plot of genes upregulated/downregulated in Prdm14/ cells compared to Prdm14+/+ cells.
(B and C) GO for genes upregulated (B) and downregulated (C) in Prdm14/ cells.
(legend continued on next page)
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Figure 4. Reduced AKT-mTORC1 Signaling
in Prdm14–/– ESC-like Cells in 2i
(A) Western blot for AKT-mTORC1 signaling in
Prdm14+/+ and Prdm14/ cells (three lines for
each, 5 3 104 cells/lane, MEFs only, 2.5 3 103
cells/lane).
(B) Quantification of pS240/244-S6 and pT389-
p70S6K levels in Prdm14+/+ and Prdm14/ cells.
The mean relative intensities against TUBA in
Prdm14+/+ and Prdm14/ cells (three lines for
each) are shown with SEMs, with the mean value
of Prdm14+/+ cells set as 1.0.
(C) Western blot for pS240/244-S6 in Prdm14/:
nGFP, Prdm14/: AG-P14, and Prdm14/:
TCL1 cells (two lines for each).
(D) Quantification of pS240/244-S6 levels in
Prdm14/: nGFP, Prdm14/: AG-P14, and
Prdm14/: TCL1 cells. The mean relative inten-
sities against TUBA (two lines for each) are shown
with SEMs, with the mean value of Prdm14/:
AG-P14 cells set as 1.0.
(E and F) Proliferation of Prdm14/: nGFP (red),
Prdm14/: AG-P14 cells (blue), and Prdm14/:
TCL1 cells (yellow) in 2i (E) or in serum (F). The
mean values (three lines for each) are shown
(log10) with SEMs.
Cell Stem Cell
PRDM14 Ensures Naive Pluripotency in Mouse ESCsmethylated in Prdm14/ cells and in EpiLCs, but not in
Prdm14+/+ cells (Figures S5A–S5C). We analyzed the methyla-
tion level of the R3 by bisulfite sequencing, which showed that
in contrast to Prdm14+/+ cells, the Prdm14/ cells bear highly
methylated R3 [11.8% and 11.0% for Prdm14+/+ versus 58.8%
and 56.2% for Prdm14/] similar to those in EpiLCs (63.4%)
(Figure 6B).
In 2i, we established Prdm14+/+ cell lines overexpressing
Dnmt3a2/Dnmt3b1 as well as those overexpressing Dnmt3a2/
Dnmt3b1/Dnmt3l, and analyzed the methylation levels of Tcl1
in these cells by bisulfite sequence. Compared to the wild-type
cells (18.1%, 7.5%, and 7.9%), two lines overexpressing
Dnmt3a2/Dnmt3b1 (41.9% and 30.8%) and three lines overex-
pressing Dnmt3a2/Dnmt3b1/Dnmt3l (51.7%, 56.6%, and
54.6%) exhibited higher methylation of the R3 of Tcl1 (Figures
6C and 6D). In particular, the ESCs overexpressing Dnmt3a2/
Dnmt3b1/Dnmt3l exhibited methylation equivalent to that in
Prdm14/ cells and in EpiLCs, and repressed Tcl1 (Figure 6E),
demonstrating that, consistent with the fact that DNMT3L asso-
ciates with DNMT3A and DNMT3B to stimulate their enzymatic
activities (Suetake et al., 2004), upregulation of each ofDnmt3a2,
Dnmt3b1, and Dnmt3L contributes to the aberrant methylation
and repression of Tcl1 in Prdm14/ cells.(D) Expression levels of key genes in Prdm14/ cells. For each gene, the averag
lines for each) and is shown (log2) with SEMs. Triangles indicate direct targets o
(E) AG-P14 peaks and their overlap with the data from a previous report (Ma et a
(F) Pie graph for the distribution of the location of AG-P14 peaks from the TSSs.
(G) Target analysis for genes upregulated/downregulated in Prdm14/ cells.
(H and I) Transcriptional regulators that co-occupy PRDM14 targets (Table S3).
co-occupancy (H) and the tag density around the PRDM14 peaks (I) are shown.
(J) Motif analysis for the PRDM14 targets based on the present (left) and previou
(K) Genes bound by PRDM14 among those upregulated and downregulated in P
See also Figure S3, Table S1, Table S2, Table S3, and Table S6.
CThe genes in theRhox cluster and those associatedwith germ-
line development, including Adam, Brdt, Dpep3, Miwi, Spo11,
Sycp1, Sycp3, Testisin, Tex12, Tpap, Tssk2, Dppa3, and Dazl,
acquire de novo promoter methylation in E6.5 epiblasts/E9.5
embryos by their de novo DNMT activity (Borgel et al., 2010;
Oda et al., 2006). Notably, Rhox5 and Rhox6 were repressed in
Prdm14/ cells (Table S1).We therefore evaluated the promoter
methylation of these genes in Prdm14+/+ and Prdm14/ cells.
We digested the genome of these cells by HpaII, followed by
quantification of the undigested (methylated) promoter by
gene-specific Q-PCR (HpaII-Q-PCR) (Figure S5D). We used
the undigested genome of Prdm14+/+ ESCs as a control for
100% methylation and the digested genome of the Dnmt1/
Dnmt3a/Dnmt3b triple-knockout (TKO) ESCs (Tsumura et al.,
2006) as a negative control for 0% methylation. Remarkably,
most of the genes analyzed showed higher promotermethylation
in Prdm14/ cells than in Prdm14+/+ cells (Figure 6F). Notably,
the promoter of Dppa3, which did not show higher methylation
in Prdm14/ cells (Figure 6F), is not methylated in E6.5
epiblasts, but becomes methylated in older E9.5 embryos (Bor-
gel et al., 2010).
Furthermore, bisulfite sequence analysis of the promoters for
the repetitive sequences long interspersed nuclear element 1e Ct value in Prdm14/ cells was subtracted by that in Prdm14+/+ cells (three
f PRDM14 identified by ChIP-seq analysis.
l., 2011).
(*), data from Chen et al. (2008); (**), data from Pasini et al. (2010). Percentage
s (right) study (Ma et al., 2011).
rdm14/ cells.








Figure 5. Hyperactive FGFR Signaling in Prdm14–/– ESC-like Cells
(A and B) Expression levels of the indicated genes in Prdm14/ cells in 2i (A) and after 2-day culture in serum (B). For each gene, the average Ct value in
Prdm14/ cells was subtracted from that in Prdm14+/+ cells (three lines, two technical replicates for each) and is shown (log2) with SEMs.
(legend continued on next page)
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PRDM14 Ensures Naive Pluripotency in Mouse ESCs(LINE1) and intracisternal A particle (IAP) revealed that,
compared to Prdm14+/+ cells, the Prdm14/ cells bear signifi-
cantly higher methylation levels in these sequences, and their
levels were similar to those in the EpiLCs (Figures 6G and 6H),
indicating that the Prdm14/ cells acquire higher DNA methyl-
ation at the genome-wide level. We conclude that PRDM14
represses de novo DNMT activities and prevents an aberrant
genome-widemethylation, and consequently activates a number
of genes, including Tcl1, which play roles in the naive state ESCs.
PRDM14 and the Epigenetic Metastability of mESCs
in Serum
The finding that PRDM14 regulates gene expression through the
repression of de novo DNMTs led us to speculate that the meta-
stability of mESCs in serum may involve a similar mechanism.
We cultured single P14DExV-high and P14DExV-low/no cells
(Figure S6A) independently at a low density in serum. After
only 48 hr of culture, some cells in the colonies from P14DExV-
high cells lost P14DExV and NANOG expression, whereas as
many as 33% of the cells in the colonies from P14DExV-low/no
cells gained P14DExV andNANOG in the resulting colonies, con-
firming the metastability of mESCs in serum (Figures S6B and
S6C). Compared to the P14DExV-high cells, the P14DExV-low/
no cells exhibited a higher expression of Dnmt3a/DNMT3A and
Dnmt3b/DNMT3B, but a similar expression of Dnmt3l/DNMT3L
(Figure 1C, Figure S6D), suggesting that serum overrides the
repressive effect of PRDM14 onDnmt3l. We examined themeth-
ylation of Tcl1, which revealed that Tcl1 in P14DExV-high and
P14DExV-low/no cells showed a low (3.6%) and a high (66.7%)
methylation, respectively (Figures S6E and S6F). The mecha-
nism of the demethylation of relevant genes including Tcl1 in
metastable ESCs is unknown, but may involve TET (ten-eleven
translocation) di-oxygenases (Figures S6G–S6I) (Ficz et al.,
2011). These data suggest that PRDM14 regulates the metasta-
bility of mESCs in serum, at least in part, by a de novo DNMT-
mediated epigenetic mechanism.
PRDM14 Represses Gene Expression by Recruiting
PRC2
The genes repressed by PRDM14 in 2i are enriched with those
bound by NANOG and SUZ12 (Figure 3G), a key component of
PRC2, which mediates histone H3 lysine 27 trimethylation
(H3K27me3) for gene repression (Margueron and Reinberg,
2011). We therefore examined whether PRDM14 may associate
with these proteins for gene repression. We established the(C) Western blot for pERK1/2 levels in Prdm14+/+ and Prdm14/ cells in 2i (left) o
MEFs only, 2.5 3 103 cells/lane). The relative intensities of pERK1/2 against ER
(D) Western blot for pERK1/2 in Prdm14+/+ and Prdm14/ cells (cultured in ser
exposure to FGF4 (3 ng/ml) for the indicated times (5 3 104 cells/lane, MEFs o
(E) Proliferation of Prdm14+/+ and Prdm14/ cells (three lines for each) in serum
with SEMs.
(F) Colonies stained for AP activity of Prdm14+/+ and Prdm14/ cells transferred
(G) Gene expression in Prdm14+/+ and Prdm14/ cells cultured in serum with FG
0 and the differences from these values are indicated (log2) with SEMs (three line
(H) PCA of global expression profiles ofPrdm14+/+,Prdm14/,Prdm14/: AG-P
2), and of day 2 and day 3 EpiLCs (Hayashi et al., 2011).
(I) Expression of key genes in (H). The mean Ct values of Prdm14+/+ cells are set
lines, two technical replicates for each).
See also Figure S4, Table S4, and Table S6.
CPrdm14/: AG-P14 cell line expressing the biotin ligase (Cull
and Schatz, 2000) and precipitated the AG-P14 by using strep-
toavidin-conjugated beads. SUZ12 and JARID2, the latter of
which recruits PRC2 to target genes (Margueron and Reinberg,
2011), but not NANOG or SIN3A, the latter of which is a key
component of histone deacetylase complexes (Grunstein,
1997), were coprecipitated with AG-P14 (Figure 7A). When the
cells were immunoprecipitated with SUZ12, we detected
JARID2 and AG-P14, and when they were immunoprecipitated
with JARID2, we detected endogenous PRDM14 in the precipi-
tates (Figures 7B and7C). These findings suggest that onemech-
anism by which PRDM14 represses its target genes is mediated
through PRC2.
We performed ChIP-seq analyses of the genome-wide locali-
zation of H3K27me3 and SUZ12 in Prdm14+/+ and Prdm14/
cells in 2i (Figures S7A–S7C). We identified the genomic loci
where both the H3K27me3 and SUZ12 tag densities were
reduced bymore than 50% inPrdm14/ cells (7,826 loci in total,
corresponding to 1,568 genes [the H3K27me3 and SUZ12 peaks
within 50 kb from the TSSs]) and calculated the distance of these
loci from their nearest PRDM14-binding sites (Table S5). This
analysis showed that (1) these loci are enriched in regions close
to the PRDM14-binding sites (Figure 7D) and (2) the genes
repressed by PRDM14, including Dnmt3a, Dnmt3b, Fgfr1, and
Hs6ts2, are enriched in regions close to the reduced
H3K27me3 and SUZ12 loci: PRDM14 affects PRC2 recruitment
into regions as far as10 kb from the PRDM14-binding sites and
the genes repressed by PRDM14 associate with SUZ12 within
10 kb from their TSSs (Figures 7D, 7F, and 7G, Figures S7D–
S7F). Among the 280 genes upregulated in Prdm14/ ESCs,
59 (21.1%) genes showed reduced H3K27me3 and SUZ12
levels within 50 kb from their TSSs (Figure S7F, Table S5). In
sharp contrast, the genomic loci where both the H3K27me3
and SUZ12 tag densities were elevated more than 2-fold in
Prdm14/ cells (5,853 loci in total, corresponding to 2,249
genes) were randomly distributed with regard to their nearest
PRDM14-binding sites, and the genes activated by PRDM14
showed no enrichment in association with the elevated
H3K27me3 and SUZ12 loci (Figure 7E).
We validated the effects of the loss of PRDM14 on the
chromatin modification state of and the PRC2 binding to seven
and eight sites, including the PRDM14-binding site around the
upstream/promoter region of Fgfr1 and Dnmt3b, respectively,
in Prdm14+/+ and Prdm14/ cells by ChIP-Q-PCR (Figure 7H,
Figures S7G–S7K). H3K27me3 was enriched in the flankingr after 2-day exposure to serum (right) (three lines for each,53 104 cells/lane,
K1/2 in each line are shown at the top of the pERK1/2 blot (right).
um-free medium with N2B27 and with GSK3i, but without MEKi and LIF) after
nly, 2.5 3 103 cells/lane).
with or without FGFRi (Fi) or MEKi (Mi). The mean values are shown (log10)
to serum (top) or serum with FGFRi (bottom) for 9 days. Bar, 500 mm.
FRi for more than 1 month. The mean Ct values of Prdm14+/+ cells are set as
s, two technical replicates for each).
14 cells in 2i, serum (day 2), serumwithMEKi (day 2), and serumwithout LIF (day
as 0 and the differences from these values are indicated (log2) with SEMs (two
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Figure 6. Elevated DNA Methylation in Prdm14–/– ESC-like Cells in 2i
(A) Western blot for de novo DNMTs in Prdm14+/+ and Prdm14/ cells (three lines for each, 5 3 104 cells/lane, MEFs only, 2.5 3 103 cells/lane).
(B) Bisulfite sequence analysis (BS) for methylation levels of the R3 (see Figure S5A) in Prdm14+/+ and Prdm14/ cells (two lines for each), and in day 2 EpiLCs.
Unmethylated and methylated CpG sites are indicated by white or black circles, respectively. Percentage of methylation is shown at the bottom.
(C) BS for methylation levels of the R3 in Prdm14+/+ ESCs overexpressing nGFP, Dnmt3a2 and Dnmt3b1, Dnmt3a2, Dnmt3b1, and Dnmt3l (three lines for each).
(D) Themethylation levels of the R3 in Prdm14+/+: nGFP and Prdm14+/+: 3A2+3B1+3L cells (three lines for each) in (C). Themean percentages of methylations are
shown with SEMs.
(E) Expression levels of Pou5f1, Sox2, and Tcl1 in Prdm14+/+: 3A2+3B1+3L cells (eight lines). The mean Ct values in Prdm14+/+: nGFP cells (two lines) are set as
0 and the differences from these values are indicated (log2) with SEMs (two technical replicates).
(F) HpaII-Q-PCR for promoter methylation levels of the indicated genes in Prdm14+/+ and Prdm14/ cells (three lines for each), and in Dnmt1/Dnmt3a/Dnmt3b
triple-knockout (TKO) ESCs. Nondigested genome DNA (ND) was used as a control for 100%methylation. For each cell line, the percentage of methylation levels
as compared to the ND are shown (log10) with SEMs (two technical replicates).
(legend continued on next page)
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PRDM14 Ensures Naive Pluripotency in Mouse ESCsregions of the PRDM14-binding sites in Prdm14+/+ cells, but was
substantially reduced in Prdm14/ cells (Figure 7H, Figure S7I).
JARID2 and SUZ12 were both bound to the region around the
PRDM14-binding sites in Prdm14+/+ cells, but were not as en-
riched in Prdm14/ cells (Figure 7H, Figure S7J). Conversely,
H3K27 acetylation (H3K27ac), a modification associated with
active transcription (Rada-Iglesias et al., 2011), was maintained
at a low level in Prdm14+/+ cells, but was highly enriched at all
the sites in Prdm14/ cells (Figure 7H). NANOG co-occupied
the PRDM14-binding site and the enrichment of NANOG at the
PRDM14-binding site was reduced in Prdm14/ cells (Fig-
ure 7H). p300, a histone acetyltransferase, showed enrichment
at the PRDM14-binding site in both Prdm14+/+ and Prdm14/
cells (Figure 7H). Collectively, these findings demonstrate that
PRDM14 regulates the level of H3K27me3 at many loci distrib-
uted in a genome-wide manner and that the PRDM14-depen-
dent deposition of H3K27me3 represses a number of genes,
including those with key functions for the regulation of the
ground-state pluripotency (Figure 7I).
DISCUSSION
Most studies on the function of transcription factors in mESCs
have been performed in serum. Our study points to the impor-
tance of conducting such studies in 2i. PRDM14 co-occupies
many genes with OCT4, SOX2, and NANOG, and occupies
Pou5f1 and Sox2 (Figures 3H and 3I) (Ma et al., 2011). PRDM14
therefore appears to be critical for the core pluripotency circuitry.
However, the Prdm14/ ESC-like cells maintain the expression
of these factors and remain pluripotent, when shielded from the
FGFR signaling (Figures 2D and 3D), demonstrating that the
core pluripotency circuitry per se is sustainable without
PRDM14 and that impairment of pluripotency without PRDM14
is the secondary effect of hyperactive FGFR signaling (Figure 7I).
The mechanism that induces ESC differentiation downstream of
MAPK remains unknown. We did not detect a clear difference in
the upregulation of known downstream targets of FGFR (Egr1,
Spry, and Dusp) between Prdm14+/+ and Prdm14/ cells after
FGF4 or serum treatment (Figures S4E and S4F), indicating that
an as-yet-unidentified target of FGFR signaling plays a key role
in the priming of ESC differentiation.
A previous study showed that PRDM14 blocks mESCs from
differentiating into ExEn lineages (Ma et al., 2011). This is based
on the observation that, 5–7 days after the RNAi-mediated KD of
Prdm14 (50% KD), mESCs in serum differentiated into ExEn-
like cells. In contrast, when exposed to serum, the Prdm14/
cells differentiated toward an epiblast-like state in only 2 days,
and then eventually disappeared (Figure 5). The transcriptome
analysis indicated that serum induces naive ESCs into an
epiblast-like state, and this effect is antagonized by LIF, MEKi,
and PRDM14 (Figure 5H). The difference between the two
studies may have arisen from the relatively low KD efficiency
(50% KD) of the previous study or may have been because
the epiblast-like cells induced by PRDM14 KD were not main-(G) BS for methylation levels in LINE1 and IAP in Prdm14+/+ (four lines) and Prdm
(H) Quantification of themethylation levels of LINE1 and IAP inPrdm14+/+ (four line
are shown with SEMs.
See also Figures S5 and S6 and Table S6.
Ctained properly in the previous study and, as a result, stable
ExEn-like cells persisted predominantly.
PRDM14 is expressed highly in hESCs and its KD by RNAi
leads to their rapid differentiation (within 4 days), with acute
downregulation of POU5F1, SOX2, and NANOG (Chia et al.,
2010; Tsuneyoshi et al., 2008). PRDM14 was shown to regulate
the expression of POU5F1 directly through binding to one of its
conserved regulatory elements (Chia et al., 2010). These findings
suggest that PRDM14 functions differently in hESCs than in
mESCs. In fact, the pluripotency of hESCs depends on FGFR
signaling (Thomson et al., 1998), which is a direct target for
repression by PRDM14 in mESCs (Figure 3D, Figure 5, and
Figures S3C and S3D). Among the targets of PRDM14 in mESCs
involved in FGFR signaling, only FGFR1 seems also to be a target
of PRDM14 in hESCs (Chia et al., 2010). The mechanistic basis
for the differential function of PRDM14 between hESCs and
mESCs warrants further investigation.
We showed that, unlike JARID2, a well-known regulator of
PRC2 (Margueron and Reinberg, 2011), PRDM14 regulates
a fraction of PRC2 targets (Figures 7D and 7E and Figure S7F).
Notably, PRDM14 associates with JARID2 and regulates
the association of JARID2 with the genome (Figure 7H),
although JARID2 itself can also bind DNA. While JARID2 is
widely expressed, binds to GC-rich sequences, and controls
a majority of PRC2 targets (Margueron and Reinberg, 2011),
PRDM14 shows specific expression, binds specific sequences,
and recruits PRC2 onto genes whose repression is critical
for naive pluripotency. Consistently, while disruption of
PRC2 components such as Suz12 and Jarid2 results in a null
potency of ESCs (ectopic expression of developmental genes,
misregulation of pluripotency genes, and inability to differen-
tiate) (Margueron and Reinberg, 2011), Prdm14 is specifically
required for the retention of a naive pluripotency in serum,
and Prdm14/ cells are able to differentiate into somatic
lineages.
The Prdm14/ ESC-like cells differentiate primarily into
neurons, but form tissues of three germ layers in teratomas
and contribute to chimeras (Figure 2). This is rather surprising,
but indicates that a variety of phenotypes of Prdm14/ cells
in 2i, including epigenetic alterations toward an epiblast-like
state (Figure 6), are tolerated and properly accommodated
during embryonic development. In mouse development,
Prdm14 shows transient expression in a Nanog-positive popula-
tion of ICM cells at around E3.5, disappears by E4.5, regains
only in PGC precursors at around E6.5, and shows a high
expression (Figure S1) (Kurimoto et al., 2006, 2008; Yamaji
et al., 2008). The Prdm14/ embryos develop apparently nor-
mally, at least on mixed backgrounds, but they fail to specify
PGCs (Yamaji et al., 2008). Nonetheless, it cannot be excluded
that the chimeras of Prdm14/ cells or the Prdm14/ mice
possess certain abnormalities, including those of epigenetic
origin resulting from the absence of PRDM14 in early embryonic
cells (Wadhwa et al., 2009). Considering the severe defect upon
KD of PRDM14 in hESCs, PRDM14 may have more significant14/ cells (three lines), and in day 2 EpiLCs.
s) andPrdm14/ cells (three lines) in (G). Themean percentages of methylation
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Figure 7. PRDM14 Represses Gene Expres-
sion through Association with PRC2
(A–C) Immunoprecipitation of AG-P14 (A), SUZ12
(B), and JARID2 (C) followed by western blot for
AG-P14, JARID2, SUZ12, NANOG, and SIN3A (A),
for SUZ12, JARID2, AG-P14, and GFP (B), and for
JARID2 and PRDM14 (C) in Prdm14/: nGFP and
Prdm14/: AG-P14 cells (A and B) and in
Prdm14+/+ cells (C).
(D and E) Frequency distribution of distance-from-
immediate-PRDM14-peaks of loci that have both
SUZ12- and H3K27me3-tag densities reduced (D)
or elevated (E) in Prdm14/ cells as compared to
Prdm14+/+ cells. Colors indicate loci within 50 kb
from the TSSs of genes with expression upregu-
lated (red), downregulated (blue), and not signifi-
cantly changed (gray) in Prdm14/ cells, and loci
located farther than 50 kb from TSSs (black).
(F andG) ChIP-seq tracks of PRDM14, SUZ12, and
H3K27me3 in the vicinities to TSSs of Fgfr1 (F) and
Dnmt3b (G) in Prdm14+/+ (black) and Prdm14/
(red) cells. The fold changes of normalized tag
densities of SUZ12 and H3K27me3 in Prdm14/
cells as compared to Prdm14+/+ cells are repre-
sented with blue and red lines, respectively.
Significant changes in SUZ12 and H3K27me3
(>2-fold) are indicated with red bars below the
tracks. The orange vertical bars indicate the loci
used for ChIP-Q-PCR analysis. The ChIP-seq
tracks of PRDM14 and SUZ12 in previous
publications (Ma et al., 2011; Pasini et al., 2010) are
also shown.
(H) ChIP-Q-PCR for the enrichment of the indi-
cated factors on the seven regions [indicated by
orange vertical bars and numbers in (F)] in
Prdm14+/+ (black) and Prdm14/ cells (red). The
enrichment of each factor (two technical repli-
cates) is indicated by percentage input, with SEMs.
(I) A model of the function and the mechanism of
action of PRDM14 in mESCs.
See also Figure S7, Table S3, Table S5, and
Table S6.
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PRDM14 Ensures Naive Pluripotency in Mouse ESCsfunction in the early development of mammals other than the
mouse, a possibility that warrants investigation.EXPERIMENTAL PROCEDURES
The experimental procedures for animals, isolation of preimplantation
embryos, ESC derivation, immunosurgery, FACS analysis, colony formation
assay, teratoma formation, generation of chimeras, plasmid construction,380 Cell Stem Cell 12, 368–382, March 7, 2013 ª2013 Elsevier Inc.establishment of stable transfectants, GO and
EASE analysis, immunofluorescence analysis,
immunohistochemistry and AP staining, immuno-
precipitation and western blot analysis, bisulfite
sequencing analysis and COBRA, and HpaII-
digestion-Q-PCR are available in the Supple-
mental Information.
ESC Derivation
The derivation of ESCs under the serum+LIF or the
2i+LIF condition was performed as described inWakayama et al. (2001) or in Hayashi et al. (2011), respectively.
Q-PCR and Microarray Analysis
Prior to the analysis, we removed MEFs by culturing dissociated ESCs in
2i+LIF for 30 min and harvesting floating populations of cells. RNA was ex-
tracted with a QIAGEN RNeasy Mini or Micro Kit (74134). Lysate was passed
through QIAshredder columns. DNase treatment was performed by using
a TURBO DNA-free Kit (cat#AM1907; Invitrogen). Five hundred to one thou-
sand nanograms of total RNA was used for synthesizing cDNA with oligo(dT)20
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PRDM14 Ensures Naive Pluripotency in Mouse ESCsprimer by using a SuperScript III First-Strand Synthesis System for RT-PCR
(cat#18080-051; Invitrogen) and diluted twenty-fold with water. Two microli-
ters of RT product was used for each Q-PCR reaction. Relative gene expres-
sion analysis using Q-PCR was performed with an ABI 7300 Real-Time PCR
System (Applied Biosystems/Life Technologies), a LightCycler 480 System II
(Roche, Indianapolis, IN) or a CFX384 Real-Time PCR Detection System
(BioRad, Hercules, CA) in conjunction with Power SYBR Green PCR Master
Mix (cat#4367659; Applied Biosystems/Life Technologies). The primers used
are listed in Table S6.
For Affymetrix expression analysis, spike RNAs were added to the total RNA
to estimate the absolute copy numbers of transcripts. Microarray hybridization
to an Affymetrix GeneChip Mouse Genome 430.2 Array was performed
according to the manufacturer’s instructions. The microarray data were pro-
cessed using dChip software (Li and Wong, 2001) as described previously
(Kurimoto et al., 2006). The CEL data were normalized together with the day
2 and 3 EpiLCs data (Hayashi et al., 2011) (GEO accession number
GSE30056). PCA was performed using the program prcomp in the program
suit R (R Development Core Team, 2010) and 7,194 selected probes with
a >2-fold difference in expression in at least one pair-wise comparison and
an expression level of >256 arbitrary signal units in at least one sample.
ChIP-Seq Analysis
The preparation of ChIP DNA was performed as described previously (Katou
et al., 2006). ESCs at 70%–80% confluency (approximately 2 3 107 cells on
15 cm dish) were crosslinked with 1% formaldehyde for 5 min at RT and rinsed
twice with 10 ml of cold PBS after being quenched with 125mM glycine. The
fixed cells were harvested by a silicon scraper, collected by centrifugation at
7003 g for 5 min at 4C, resuspended in 5 ml of cold LB1 (20 mM Tris,
10 mM NaCl, 2.5 mM MgCl2, 0.2% NP-40, and 1 mM PMSF [pH 7.5]), and
pelleted by centrifugation at 1,350 3 g for 5 min after the rotation for 10 min
at 4C. The pellet was resuspended in 5 ml of LB2 (20 mM Tris, 200 mM
NaCl, 1 mM EDTA, 0.5 mM EGTA, and 1 mM PMSF [pH 8.0]) and rotated for
10 min at 4C. The nuclei were pelleted by centrifugation at 1,350 3 g for
5 min at 4C and lysed in 2 ml of LB3 (20 mM Tris, 150 mM NaCl, 1 mM
EDTA, 0.5 mM EGTA, 1% Triton X-100, 0.1% sodium deoxycholate, 0.1%
SDS, and Complete EDTA-free). The lysed nuclei were sonicated using the
following conditions: Branson Sonifier 250D with standard tip; 15% output;
10 cycles (12 s ON, centrifugation at 13,200 3 g for 2 min at 4C).
Protein-DNA complexes were immunoprecipitated overnight at 4C using
10 mg of antibodies bound to 250 ml of Dynabeads Protein G (Invitrogen).
Immunoprecipitates were washed five times with 1 ml of RIRA buffer (50 mM
HEPES-KOH, 0.5 M LiCl, 1 mM EDTA, 0.5% Na-Deoxycholate, and 1%
NP-40 [pH 7.4]), and once with 250 ml of TE50 (50 mM Tris and 10 mM EDTA
[pH 8.0]). Beads were resuspended with 200 ml of EB (1% SDS and TE50).
The complexes were eluted at 65C for 20 min. The crosslinks for both the
immunoprecipitated and input DNA fragments were reversed by incubating
at 65C for at least 6 hr. After RNase A and Proteinase K digestion, the DNA
was purified by phenol/chloroform extraction and EtOH precipitation with
30 mg glycogen and dissolved with TE. The procedures for massively parallel
sequencing are described in the Supplemental Information.
ACCESSION NUMBERS
The accession numbers for the microarray expression and ChIP-seq data re-
ported in this paper are GSE42580 and GSE42616, respectively.
SUPPLEMENTAL INFORMATION
Supplemental Information for this article includes six figures, six tables, and
Supplemental Experimental Procedures and can be found with this article on-
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